This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...

The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity.

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.